Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To determine the maximum tolerated dose (MTD) of Dasatinib in relapsed or refractory
non-hodgkin's lymphoma (NHL) patients and to determine the safety of Dasatinib in NHL.
Secondary Objectives:
- To assess the complete and overall response rates for all Phase I and Phase II patients
and to determine overall survival and event free survival for all Phase I and Phase II
patients.
- To assay the levels of kinase activity in NHL specimens and correlate this activity to
patient outcomes.